# Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer

> **NCT04983095** · NA · RECRUITING · sponsor: **Karin Soderkvist** · enrollment: 118 (estimated)

## Conditions studied

- Prostate Cancer Metastatic
- Radiation Therapy
- Positron-Emission Tomography

## Interventions

- **RADIATION:** stereotactic body radiotherapy
- **COMBINATION_PRODUCT:** androgen deprivation therapy
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT04983095
- **Lead sponsor:** Karin Soderkvist
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-27
- **Primary completion:** 2031-12-31
- **Final completion:** 2033-12
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04983095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04983095, "Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04983095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*